Supriya Lifescience Ltd Stock Price Today (NSE: SUPRIYA)
Fundamental Score
Supriya Lifescience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Supriya Lifescience Ltd share price today is ₹914.35, down 3.44% on NSE/BSE as of 17 June 2026. Supriya Lifescience Ltd (SUPRIYA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.00K (Cr). The 52-week high for SUPRIYA share price is ₹1085.00 and the 52-week low is ₹545.50. At a P/E ratio of 32.91x, SUPRIYA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 20.75% and a debt-to-equity ratio of 0.00.
Supriya Lifescience Ltd Share Price Chart — NSE/BSE Historical Performance
Supriya Lifescience Ltd share price chart: 14.59% return over the past month. 52-week high ₹1085.00, 52-week low ₹545.50.
Supriya Lifescience Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1026.20 | ₹1026.20 | ₹903.00 | ₹917.25 | 22.58L (Cr) | |
| ₹990.00 | ₹1085.00 | ₹958.55 | ₹1052.50 | 50.22L (Cr) | |
| ₹887.30 | ₹968.70 | ₹848.05 | ₹968.70 | 58.03L (Cr) | |
| ₹807.25 | ₹807.25 | ₹807.25 | ₹807.25 | 0.00 (Cr) | |
| ₹789.00 | ₹818.00 | ₹785.00 | ₹807.25 | 5.32L (Cr) | |
| ₹766.30 | ₹782.00 | ₹765.05 | ₹780.95 | 2.09L (Cr) | |
| ₹775.80 | ₹787.00 | ₹762.15 | ₹766.15 | 1.88L (Cr) | |
| ₹739.90 | ₹794.00 | ₹731.35 | ₹774.10 | 10.46L (Cr) | |
| ₹733.95 | ₹742.35 | ₹721.00 | ₹733.90 | 1.94L (Cr) | |
| ₹722.85 | ₹731.90 | ₹711.00 | ₹725.25 | 1.51L (Cr) |
Supriya Lifescience Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹990.00 | ₹1085.00 | ₹903.00 | ₹917.25 | -7.35% | |
| ₹694.90 | ₹968.70 | ₹666.00 | ₹968.70 | +39.40% | |
| ₹569.95 | ₹717.45 | ₹569.95 | ₹694.90 | +21.92% | |
| ₹620.70 | ₹649.00 | ₹545.50 | ₹561.90 | -9.47% | |
| ₹670.20 | ₹721.00 | ₹649.95 | ₹655.00 | -2.27% | |
| ₹753.00 | ₹775.00 | ₹658.00 | ₹676.05 | -10.22% | |
| ₹751.15 | ₹762.80 | ₹706.85 | ₹751.50 | +0.05% | |
| ₹778.00 | ₹832.40 | ₹724.75 | ₹747.50 | -3.92% | |
| ₹729.90 | ₹799.80 | ₹680.70 | ₹776.90 | +6.44% | |
| ₹653.96 | ₹754.80 | ₹641.00 | ₹729.05 | +11.48% | |
| ₹660.20 | ₹699.04 | ₹616.30 | ₹651.81 | -1.27% | |
| ₹711.75 | ₹749.10 | ₹645.85 | ₹661.25 | -7.10% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Supriya is a mid-cap API exporter transitioning to formulations, but execution risk is high.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Supriya Lifescience closed the week ending April 10, 2026, with a 3.50% gain, closing at The stock experienced a significant gap up on April 8, 2026, opening near a 9.21% increase. The company is expected to announce Q4 FY26 results in May 2026, with analysts projecting revenue of -380 Cr and PAT of -110 Cr.
CORE STORY (THE REAL GAME)
Supriya is transitioning from a pure-play API manufacturer to a more integrated player with CMO and finished dosage capabilities. The market is watching to see if they can execute this transition and sustain margins.
- Q4 results expected in May 2026 will be a key catalyst
- Recent gain of 3.50% shows positive momentum
- Ramping up capacity utilization
- Positive Q4 results with strong guidance
- New order wins in the CMO business
- Successful commissioning of the Ambernath facility
- Negative free cash flow
- Intense competition in the API market
- SME-cap liquidity risk
FII decreased holdings by 1.32%, while DII increased holdings by 0.36%
Indian pharma industry is transitioning towards value-led innovation in biologics and biosimilars
New 10-year CMO contract with a European firm to generate peak revenue of ₹60 crores annually starting FY27
No, Free Cash Flow 5Y: ₹-56.28 Cr
Focus on commissioning the new formulation facility and scaling up the CMO business. Key monitorable is margin sustainability.
Primary Thesis Risk
Failure to diversify beyond APIs will lead to margin compression and derating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Supriya Lifescience Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Supriya Lifescience Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUPRIYA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.75%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.46%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (20.31%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (20.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (131.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (-14.16% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-56.28 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Supriya Lifescience Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Supriya Lifescience Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Supriya Lifescience LtdSupriya Lifesci...Selected✓ SUPRIYA • 543434 | 62.2/100 | ₹914.35₹914 | ₹6001.22₹6001.22 | 32.91Average 32.9 Average | 20.75%Excellent 20.75% Excellent | 27.46%Excellent 27.46% Excellent | 0.00Excellent 0.0 Excellent | 20.71%Excellent 20.71% Excellent | 17.45%Excellent 17.45% Excellent | 0.13% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Supriya Lifescience Ltd PE Ratio History
Historical price-to-earnings ratio for SUPRIYA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹23.35 | ₹751.50 | 32.2x |
| FY 2024 | ₹14.80 | ₹739.80 | 50x |
| FY 2023 | ₹11.16 | ₹314.75 | 28.2x |
| FY 2022 | ₹18.86 | ₹235.05 | 12.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Supriya Lifescience Ltd Dividend History
Annual cash dividends paid by SUPRIYA — dividend yield 0.13%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹6.44 Cr |
| FY 2024 | ₹4.83 Cr |
| FY 2023 | ₹4.83 Cr |
| FY 2022 | ₹4.39 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Supriya Lifescience Ltd Quarterly Performance
Latest quarterly metrics for SUPRIYA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.31%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.27%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
17.45%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.71%
Compounded annual net profit growth over 5 years
Supriya Lifescience Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUPRIYA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Supriya Lifescience Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Supriya Lifescience Ltd (SUPRIYA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Supriya Lifescience Ltd
About SUPRIYA (Supriya Lifescience Ltd)
Supriya Lifescience Ltd is a dynamic pharmaceutical company focused on developing, manufacturing, and distributing high-quality active pharmaceutical ingredients (APIs) and special...ty chemicals across the globe. With a strong emphasis on innovation and customer satisfaction, Supriya strives to be a reliable partner to pharmaceutical companies worldwide, offering a diverse portfolio of products targeting a broad spectrum of therapeutic areas. The company leverages advanced manufacturing processes and a dedicated research and development team to ensure product excellence and meet the stringent regulatory requirements of the global pharmaceutical market. Supriya Lifescience is committed to advancing healthcare by providing essential building blocks for life-saving medications. The company’s comprehensive API range covers critical therapeutic segments including treatments for respiratory ailments such as antihistamines and anti-asthmatics, pain management solutions comprising analgesics and anesthetics, cardiovascular health with anti-hypertensives, and essential vitamins. Supriya also provides APIs for oncology, veterinary medicine, and general healthcare, demonstrating its wide-ranging capabilities and commitment to addressing diverse medical needs. Furthermore, the company continues to expand its product line through strategic collaborations and in-house research, solidifying its position as a versatile and adaptive player in the pharmaceutical landscape. Beyond APIs, Supriya Lifescience demonstrates its commitment to innovative healthcare solutions through the development of specialized products like GelHeal, an advanced wound care solution. This showcases the company’s dedication to addressing specific patient needs with cutting-edge technology. Driven by a customer-centric approach and a commitment to ethical practices, Supriya Lifescience Ltd aims to consistently deliver high-quality products, reliable service, and sustainable growth, contributing significantly to the advancement of global healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
SUPRIYA Share Price: Frequently Asked Questions
What is the current share price of Supriya Lifescience Ltd?
Supriya Lifescience Ltd (SUPRIYA) trades at ₹914.35 on NSE and BSE. Market cap ₹6.00K (Cr). Educational data only.
What is the P/E ratio of Supriya Lifescience Ltd?
Supriya Lifescience Ltd has a P/E of 32.91x vs industry average 31.77x.
What is the Bull Run score for Supriya Lifescience Ltd?
Supriya Lifescience Ltd has a Bull Run score of 62.2/100 based on 25+ financial parameters.
Does Supriya Lifescience Ltd pay dividends?
Supriya Lifescience Ltd has a dividend yield of 0.13%. Past dividends don't guarantee future payments.
What is the ROE of Supriya Lifescience Ltd?
Supriya Lifescience Ltd has ROE of 20.75%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Supriya Lifescience Ltd?
Supriya Lifescience Ltd has debt-to-equity of 0.00.
Is Supriya Lifescience Ltd a good investment?
Bull Run gives Supriya Lifescience Ltd a score of 62.2/100. This is not investment advice — consult a SEBI-registered advisor.